<code id='7FC4146528'></code><style id='7FC4146528'></style>
    • <acronym id='7FC4146528'></acronym>
      <center id='7FC4146528'><center id='7FC4146528'><tfoot id='7FC4146528'></tfoot></center><abbr id='7FC4146528'><dir id='7FC4146528'><tfoot id='7FC4146528'></tfoot><noframes id='7FC4146528'>

    • <optgroup id='7FC4146528'><strike id='7FC4146528'><sup id='7FC4146528'></sup></strike><code id='7FC4146528'></code></optgroup>
        1. <b id='7FC4146528'><label id='7FC4146528'><select id='7FC4146528'><dt id='7FC4146528'><span id='7FC4146528'></span></dt></select></label></b><u id='7FC4146528'></u>
          <i id='7FC4146528'><strike id='7FC4146528'><tt id='7FC4146528'><pre id='7FC4146528'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:2376

          Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials. Then, we talk to Joel Dudley, a partner at the venture firm Innovation Endeavors, about how to discern promising ideas from wastes of time when it comes to AI in biotech.

          advertisement

          For more on what we cover, here’s the latest on AI in drug development; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Unique patient identifier: Experts argue the benefits, pitfalls
          Unique patient identifier: Experts argue the benefits, pitfalls

          Therehasbeenlong-standingdebateintheUSoverwhethertoimplementauniquepatientidentifiersystem.EvanVucci

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          340B reform proposal comes out of Senate working group

          Sen.JohnThuneisoneofagroupoflawmakersthatisworkingon340Breformlegislation.BRENDANSMIALOWSKI/AFPviaGe